Resistance to carbapenems in sequence type 11 Klebsiella pneumoniae is related to DHA-1 and loss of OmpK35 and/or OmpK36 
INTRODUCTION
Carbapenems are widely used and are often the only therapeutic option for treating serious infections caused by Klebsiella pneumoniae that produces extended-spectrum b-lactamases (ESBLs) and/or AmpC b-lactamases. The recent emergence of carbapenem-resistant K. pneumoniae in various countries is therefore worrying, as antimicrobial treatment options are limited.
Carbapenem resistance in K. pneumoniae has been ascribed mainly to enzymic degradation by plasmid-borne carbapenemases of classes A (GES-2, -4, -5 and -6, and KPC enzymes), B (IMP-1 and -8, and VIM-1, -2 and -12) and D (OXA-48) (Poirel et al., 2004a; Queenan & Bush, 2007) . However, some K. pneumoniae strains have acquired carbapenem resistance despite their lack of carbapenemase production. Loss of outer-membrane proteins (OMPs), including OmpK35 and OmpK36, plays a role in carbapenem resistance in K. pneumoniae strains harbouring ESBLs (CTX-Ms or SHV-2) or plasmid-borne AmpC enzymes (ACT-1, CMY-2, CMY-4 or DHA-1) (Crowley et al., 2002; Lee et al., 2007; Yang et al., 2009) .
The aim of this study was to investigate molecular mechanisms of carbapenem resistance in clinical isolates of K. pneumoniae collected between 2007 and 2008 at a tertiary-care hospital in Korea and the clinical outcomes of resistant K. pneumoniae infection.
METHODS
Patients and strains. This study was conducted between 2007 and 2008 at a tertiary-care teaching hospital with 2000 beds in Seoul, Korea. During this period, K. pneumoniae was isolated from 3278 patients, 16 (0.5 %) of which had K. pneumoniae clinical isolates that exhibited resistance to carbapenems. The isolates were identified using a Vitek GNI card (bioMérieux). Clinical characteristics were investigated through electronic medical record review. Data including age, sex, underlying disease, number of days from hospital admission to identification of K. pneumoniae infection, prior antibiotic treatment, anatomical site of isolation and clinical outcome were obtained.
Antimicrobial susceptibility testing. Antibiotic-containing discs (Becton Dickinson) were used for routine antibiograms in a disc IP: 54.70.40.11
On: Wed, 24 Apr 2019 19:49:32 diffusion assay following CLSI (2007) guidelines. Hodge and imipenem and EDTA-sodium mercaptoacetic acid double-disc synergy (IEDDS) tests were performed on agar plates as described previously (Lee et al., 2001 (Lee et al., , 2010a . The MICs of imipenem and meropenem were determined using Etest strips (AB Biodisk) on Mueller-Hinton agar plates with or without a fixed concentration of clavulanic acid (CA; 4 mg ml
21
; Sigma-Aldrich) as an inhibitor of ESBLs, aminophenylboronic acid (APB; 300 mg ml
; Sigma-Aldrich) as an inhibitor of AmpC b-lactamase, or Phe-Arg-b-naphthylamide (PAbN; 20 mg ml
; SigmaAldrich) as an efflux pump inhibitor (Song et al., 2007) .
b-Lactamase gene identification. Detection of genes encoding AmpC b-lactamases and ESBLs was performed by PCR amplification, as described previously , using the primers listed in Table 1 . Whole-cell lysates were used as templates, and PCR products were subjected to direct sequencing. Both strands of PCR products were sequenced twice with an automatic sequencer (model 3730xl; Applied Biosystems).
Resistance gene transfer experiments. The agar mating method was used to test antimicrobial resistance gene transfer using azideresistant Escherichia coli J53 as a recipient. Transconjugants were selected on Mueller-Hinton agar supplemented with imipenem (0.5 mg ml
) and azide (100 mg ml 21 ) (Jacoby & Han, 1996) .
SDS-PAGE of OMPs. SDS-PAGE experiments were carried out to investigate alterations in OMPs, as described previously (Kaczmarek et al., 2006) , using K. pneumoniae ATCC 700603 as a control strain. Briefly, bacterial cells were disrupted by ultrasonic disintegration and the supernatants were treated with 30 % Sarkosyl (Sigma-Aldrich). After incubation for 30 min, OMPs were collected by centrifugation at 45 000 g for 1 h at 4 uC and analysed by SDS-PAGE (12.5 % acrylamide) on a Mini-PROTEAN 3 Cell apparatus (Bio-Rad). The gels were stained with Coomassie Brilliant Blue.
Analysis of lesions causing disruption of porin genes. The coding sequences of ompK35 and ompK36 from K. pneumoniae were amplified using the primers listed in Table 1 and sequenced to investigate the lesions causing disruption of the OMP genes.
PFGE. Plugs containing whole genomic DNA of the K. pneumoniae isolates were digested with XbaI. The DNA fragments were separated by PFGE using a CHEF-DRII device (Bio-Rad). PFGE conditions of XbaI macrorestriction analysis were 6 V cm 21 for 20 h, with pulse times ranging from 0.5 to 60 s at a temperature of 14 uC. A l ladder (Bio-Rad) was used as a DNA size marker. Gel images in .tiff format were exported to Molecular Analyst Fingerprinting Software version 3.2 (Bio-Rad) for analysis. Comparisons for K. pneumoniae isolates were performed using the band-based dice coefficient. Dendrograms were generated using the UPGMA method and a 1.0 % position tolerance, and DNA relatedness was calculated based on the criteria of Tenover et al. (1995) .
Multilocus sequence typing (MLST). MLST was performed using seven conserved housekeeping genes (gapA, infB, mdh, pgi, phoE, rpoB and tonB) according to protocols available at an MLST website (http:// www.pasteur.fr/recherche/genopole/PF8/mlst/Kpneumoniae.html).
RESULTS

Description of the patients
The demographic and clinical characteristics of the 16 patients are shown in Table 2 . The median age of the patients was 63.5 years (range 37-77 years). All had various underlying diseases with a median Charlson weighted comorbidity score of 6 (range 0-12). The median number of days of hospitalization from admission to identification of carbapenem-resistant K. pneumoniae was 33 days (range 1-445 days). All 16 isolates were recovered from inpatients at least 3 days after admission, except for one patient (case no. 10, isolate YMC/K070912) who was transferred from another hospital. The median number of elapsed days from the initial detection of carbapenem-susceptible K. pneumoniae to the identification of carbapenem-resistant K. pneumoniae was 17 days. All patients had a previous Table 1 . Nucleotide sequences of primers used in this study
Target gene(s)
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history of carbapenem administration within the 3 months before identification of the micro-organism. Most (13/16) of the cases were considered to be true infections, whilst three were deemed simple colonization based on the Centers for Disease Control and Prevention/National Healthcare Safety Network surveillance definitions of health-care-associated infection (Horan et al., 2008) . The 13 genuinely infected patients suffered from pneumonia (n56), skin and soft tissue infection (n54), biliary tract infection (n52), urinary tract infection (n51) and bacteraemia (n55), combined with either biliary tract infection or bed sores. Follow-up prognosis data were available for 11 of the 13 patients but not for two who were transferred to other hospitals. Two patients improved with antimicrobial treatment, whilst nine patients died within 30 days of infection, including two patients (case nos 15, isolate YMC/ K080109, and 16, isolate YMC/K071208) treated with colistin. The crude mortality rate of the 13 patients was 81.8 %.
Antimicrobial susceptibilities
According to the disc diffusion assay, all of the 16 isolates exhibited resistance to most antimicrobial agents tested, including piperacillin, amoxicillin-clavulanic acid, cephalothin, cefoxitin, ceftaxidime, cefotaxime, amikacin, gentamicin, tobramycin, trimethoprim-sulfamethoxazole and levofloxacin (data not shown). All also showed resistance to imipenem (MIC range 4-32 mg ml
21
; MIC 50 , 8 mg ml
) and meropenem (MIC range 3-24 mg ml
; MIC 50 , 6 mg ml 21 ) in an Etest (Table 3 ). APB at a fixed concentration of 300 mg ml 21 lowered the MICs of imipenem and meropenem to 0.1-0.75 mg ml 21 (8-85-fold) and 0.1-1 mg ml 21 (6-85-fold), respectively, indicating that AmpC b-lactamases may participate in the acquisition of carbapenem resistance in K. pneumoniae isolates. At the same time, CA and PAbN did not affect the MICs, indicating that ESBLs and PAbN-inhibited efflux pumps may not play a role in carbapenem resistance. All isolates exhibited negative results in Hodge and IEDDS tests (Lee et al., 2001 (Lee et al., , 2010a , indicating that they did not produce carbapenemases.
b-Lactamase genes PCR and sequencing experiments detected the bla DHA-1 AmpC b-lactamase gene in all 16 clinical isolates. The isolate YMC/K080109 also harboured the bla CMY-2 AmpC blactamase gene. The bla genes of ESBLs were detected in 12 isolates, including bla SHV-12 (n510), bla CTX-M-3 (n52), bla CTX-M-14 (n53) and bla CTX-M-15 (n51). Four isolates carried both the bla SHV-12 and the bla CTX-M genes (Fig. 1) . Genes encoding plasmid-borne carbapenemases of classes A, B and D were not detected in any of the isolates (Bae et al., 2011; Lee et al., 2010b; Poirel et al., 2004b Poirel et al., , 2011 Smith Moland et al., 2003) . Carbapenem resistance was not transferred to the recipient via conjugation in any of the 16 isolates.
OMP loss
SDS-PAGE experiments were carried out to investigate alterations in OMPs. The experiments demonstrated that 12 isolates lacked both 35 and 36 kDa OMPs (OmpK35 and OmpK36), whilst four isolates lacked only OmpK36 (Fig. 1) . Sequence analysis of the corresponding OMP genes revealed various alterations. Point mutations predicted to result in early termination of translation (premature stop codon) of the ompK36 gene were identified in three isolates (YMC/ K061018, YMC/K070402 and YMC/K080109). Insertional inactivation of the ompK36 gene by insertion sequences (ISs) such as IS1, IS4 and IS903 was observed in isolates YMC/ K070630, YMC/K071125 and YMC/K071226, respectively. Insertion of a codon interrupting the ORF of the ompK36 gene was also identified in four isolates. The ompK36 gene was not detected in isolates YMC/K070223 and YMC/ K070312. Sequencing of the ompK35 gene revealed diverse types of alteration in 15 of the 16 isolates. Point mutations predicted to result in premature termination of translation were identified in five isolates, and insertion of a codon interrupting the ORF of the ompK35 gene was found in nine isolates. The ompK35 gene was not detected in isolate YMC/ K070325.
Strain typing
MLST experiments showed that all isolates shared the same sequence type (ST), ST11 (allelic profile: gapA, 3; infB, 3; mdh, 1; pgi, 1; phoE, 1; rpoB, 1; and tonB, 4), except for one isolate (YMC/K071208), which was identified as ST48 (2-5-2-2-7-1-10). XbaI macrorestriction analysis of the 16 carbapenem-resistant K. pneumoniae isolates found two pairs of related isolates with .85 % similarity, indicating a small clonal outbreak. However, most of the isolates showed a genetic similarity of ,85 %.
DISCUSSION
Although the dissemination of KPC-producing K. pneumoniae has been reported repeatedly in many parts of the world, KPC enzymes were not detected in this study (Walsh, 2010) . Furthermore, none of our carbapenem-resistant K. pneumoniae isolates exhibited positive results in the Hodge test.
APB lowered the MICs of imipenem and meropenem for the isolates, whilst CA and PAbN did not. These results suggested that AmpC enzymes such as DHA-1 and CMY-2 may play a crucial role in acquiring carbapenem resistance, whereas ESBLs and overexpression of PAbN-inhibited efflux pumps do not. Moreover, all the isolates lacked OmpK36 and/or OmpK35 because of porin gene alterations such as disruption of porin gene ORFs by insertion of an IS or a codon and point mutations resulting in early termination of translation. The ompK36 and ompK35 genes were not detected in two isolates and one isolate, respectively. The We reported previously that the DHA-1-producing K. pneumoniae strain H224 acquired carbapenem resistance via insertional inactivation of the ompK36 gene by the IS5 element under in vivo meropenem selection pressure (Song et al., 2009) . Thus, it can be speculated that all isolates involved in this study also acquired carbapenem resistance through a mechanism similar to that utilized by strain H224. Further dissemination of these strains is anticipated as the AmpC enzymes, including DHA-1, are fairly common in K. pneumoniae.
PFGE experiments showed that epidemiological relatedness among these isolates was low. Interestingly, however, all isolates except one shared the same ST (ST11) according to MLST experiments. A survey performed in four Korean hospitals during 2004-2005 detected only four isolates of ST11 among 82 ESBL-producing K. pneumoniae isolates of 37 STs, indicating that the observed high concentration of ST11 is a peculiar phenomenon (Ko et al., 2008) . The results suggest that K. pneumoniae of ST11 might be prone to the acquisition of porin gene alterations resulting in carbapenem resistance.
The clinical outcomes of patients infected with carbapenem-resistant members of the Enterobacteriaceae are known to be very poor. A recent study by Marchaim et al. (2008) showed that the mortality rate was significantly higher for patients infected with KPC-producing Enterobacter species (33 %, 11/33) than for those infected with imipenem-susceptible strains (6 %, 2/33) (2008). Another case-control study reported by Patel et al. (2008) showed that patients associated with carbapenem-resistant K. pneumoniae (mostly KPC-producing) infection were more likely to die during hospitalization than those associated with carbapenem-susceptible K. pneumoniae infection (48 vs 20 %; Patel et al., 2008) . Clinical outcomes of carbapenem-resistant K. pneumoniae infections have been investigated repeatedly, but the outcomes of infections caused by K. pneumoniae with carbapenem resistance acquired by AmpC enzyme production combined with porin loss have never been reported. We found that the clinical outcome for patients infected with these carbapenem-resistant K. pneumoniae strains was also very poor, with an 81.8 % crude mortality rate. Risk factors for these infections might involve (i) old age (.60 years), (ii) long hospitalization (.30 days), (iii) a previous 3-month history of carbapenem administration, (iv) infection caused by AmpC enzyme-producing K. pneumoniae and (v) infection caused by K. pneumoniae of ST11.
Our study had some limitations. We only included one tertiary-care hospital, and the total number of carbapenemresistant K. pneumoniae isolates was somewhat small. However, our previous results also showed that the main mechanism of carbapenem resistance in K. pneumoniae in Korea is the production of plasmid-borne AmpC enzymes cont.
Resistance to carbapenems in ST11 K. pneumoniae combined with OMP loss . We could not investigate whether mechanisms of carbapenem resistance affected clinical outcomes because carbapenemase-producing K. pneumoniae was not recovered during the study period, despite continuous screening. Furthermore, we were unable to verify whether the high mortality rate of the study population was due to carbapenem-resistant K. pneumoniae infections or underlying co-morbidities. Such questions could be answered by well-designed case-control studies including patients infected with carbapenem-resistant orsusceptible isolates.
In conclusion, the main mechanism for acquiring carbapenem resistance in K. pneumoniae in Korea was DHA-1 AmpC enzyme production in combination with OmpK36 and/or OmpK35 loss. The clinical outcomes of infections caused by these micro-organisms were very poor, with an extremely high crude mortality rate. 
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